Johnson & Johnson: Dementia trials

The registry lists 32 Dementia studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 4Phase 3 17Phase 4 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's DiseaseTerminatedNCT02817906Phase 3Results posted
• An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's DementiaTerminatedNCT02569398Phase 2/3Results posted
• The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of LifeCompletedNCT00814658Phase 4Results posted
• A Study of JNJ-63733657 in Participants With Early Alzheimer's DiseaseTerminatedNCT04619420Phase 2
• A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha TherapyCompletedNCT04571697
• Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer DementiaCompletedNCT02360657Phase 1
• Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort StudyCompletedNCT02114372
• Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With DementiaCompletedNCT02078310Phase 1/2
• Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From DonepezilCompletedNCT01478633Phase 4
• Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily RoutineCompletedNCT01009476
• A Study on Behavioral and Psychological Symptoms of DementiaCompletedNCT00641459
• A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal DementiaCompletedNCT00416169Phase 2
• Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's DiseaseCompletedNCT00338117Phase 3
• An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month PeriodCompletedNCT00299676
• Prospective Research in Memory Clinics (PRIME)CompletedNCT00297271
• A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseCompletedNCT00291421
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's DiseaseTerminatedNCT00287742Phase 3
• Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's DiseaseCompletedNCT00283725
• A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed DementiaCompletedNCT00261573Phase 3
• A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253227Phase 3
• Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release FormulationCompletedNCT00253214Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253201Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253188Phase 3
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00253123Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00249158Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00249145Phase 3
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236574Phase 3
• Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled StudyCompletedNCT00216593Phase 3
• The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer TypeCompletedNCT00216515Phase 4
• A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseCompletedNCT00216502Phase 3
• A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular DementiaCompletedNCT00035191Phase 3
• Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's DiseaseCompletedNCT00034762Phase 3